The MPN News feed provides frequent updates on the latest happenings in the MPN World. Fresh content, with brief summary is automatically updated frequently from reliable sources. Just click on the red hyperlink to pull up the complete news item.
Make PV Reporter your “starting point” for all MPN related news.
- Mutations in the miR-142 gene are not common in myeloproliferative neoplasmsby mpn_admin at 4:33 pm
Authors: Paulina Galka-Marciniak, Zuzanna Kanduła, Adrian Tire, Wladyslaw Wegorek, Kinga Gwozdz-Bak, Luiza Handschuh, Maciej […]
- Flyer for Conference 2023by JOANN MANNINO at 12:00 am
Flyer for 13th Joyce Niblack Memorial Conference The post Flyer for Conference 2023 appeared first on MPN Education Foundation.
- 13th Joyce Niblack Memorial Conference – February 18/19, 2023by JOANN MANNINO at 11:08 pm
The post 13th Joyce Niblack Memorial Conference – February 18/19, 2023 appeared first on MPN Education Foundation.
- Dr. Mesa: Evolving Therapy of MPNs – 2022by JOANN MANNINO at 10:46 pm
The post Dr. Mesa: Evolving Therapy of MPNs – 2022 appeared first on MPN Education Foundation.
- Hematocrit levels, white blood cell counts influence thrombosis risk in polycythemia veraby mpn_admin at 3:30 pm
Aaron T. Gerds, MD, MS, spoke with Healio about the REVEAL study, results of which were presented at this year’s European Hematology […]
- The Outcome of Fatherhood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms: A Single-Institution Experienceby mpn_admin at 3:29 pm
Abstract Background Fertility is a highly complex subject; it involves more than one individual and has profound psychological and economic […]
- Introducing PAN’s Newly Expanded Transportation Fundby mpn_admin at 2:31 pm
The PAN Foundation today announced an expansion of its transportation fund, providing up to $500 per year to help eligible patients access […]
- GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bnby mpn_admin at 2:15 pm
04/13/2022 Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis […]
- AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosisby mpn_admin at 5:20 pm
– Navitoclax is being studied in myelofibrosis, a rare, difficult-to-treat blood cancer […]
- Women’s History Month – Jamile Shammo, MDby mpn_admin at 8:06 pm
Dr Jamile Shammo is a Professor of Medicine and Pathology in the Department of Internal Medicine, Division of Hematology, Oncology and […]
- Women’s History Month – Linda Resar, MDby mpn_admin at 11:08 pm
Dr. Linda Resar, is a Professor of Medicine at Johns Hopkins Medicine, where she studies molecular mechanisms leading to cancer, blood […]
- Women’s History Month – Angela Fleischman, MD, PhDby mpn_admin at 3:59 pm
Dr. Angela Fleischman is an Associate Professor of Medicine in the Division of Hematology/Oncology at the University of California, […]
- Adelaide researchers discover potential treatment for myelofibrosisby mpn_admin at 5:12 pm
By Ethan Rix by abc net Australia Posted Thu 24 Mar 2022 at 8:20pm When Bruce Glover was diagnosed with a rare blood cancer, he […]
- Updates from ASH with Dr. Mesaby JOANN MANNINO at 5:55 pm
The post Updates from ASH with Dr. Mesa appeared first on MPN Education Foundation.
- Dr. Mesa discusses FDA approval of Besremi/ropegby JOANN MANNINO at 8:42 pm
The post Dr. Mesa discusses FDA approval of Besremi/ropeg appeared first on MPN Education Foundation.
